Innovent Biologics/Altruist Biologics

Received NMPA marketing approval on Jun 19, 2020 Approved for advanced non-small cell lung cancer and metastatic colorectal cancer, adult recurrent glioblastoma, hepatocellular carcinoma, cervical cancer, ovarian cancer. A total of 8 indications have been approved and included in the NRDL

Received NMPA marketing approval on September, 2020 Approved for Diffuse large b cell lymphoma、Follicular lymphoma、Chronic lymphocytic leukemia HALPRYZA® has been approved in China for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, all of which are included in the NRDL.

In Aug 2023,SINTBILO® (tafolecimab injection) is approved by China's NMPA for the treatment of adult patients with primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia. Tafolecimab has the advantage of a longer dosing interval compare...